This was the stock's second consecutive day of losses.

Shares of Inovio Pharmaceuticals Inc. INO slipped 1.96% to $2.00 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ Composite Index COMP rising ...

INOVIO (NASDAQ: INO) has announced its participation in the Oppenheimer 35th Annual Healthcare Life Sciences Conference. Dr.

INOVIO , a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases, today announced ...

DelveInsight's“Lassa Fever Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Lassa Fever, historical and forecasted epidemiology as well as the ...

Hypertension Diagnostics (OTCMKTS:HDII – Get Free Report) and Inovio Pharmaceuticals (NASDAQ:INO – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Nasdaq provides an interactive stock information chart to view history. Downloadable stock history data table is also accessible by clicking on Data Table on the navigation tool bar. If you have ...

INO-6160 is under clinical development by Inovio Pharmaceuticals and currently in Phase I for Human Immunodeficiency Virus (HIV) Infections (AIDS). According to GlobalData, Phase I drugs for Human ...

LONDON, Jan 21 (Reuters) - President Donald Trump is pulling the U.S. out of the World Health Organization, raising concerns about the U.N. agency's ability to fight diseases and respond to ...

Recursion Pharmaceuticals has a flashy drug development platform. It has a lot to prove about whether that platform's use of AI is helpful. Some power players have backed it with significant ...

HOUSTON and CAMBRIDGE, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company developing therapies for patients with ...